

THIS ANNOUNCEMENT RELATES TO THE DISCLOSURE OF INFORMATION THAT QUALIFIES OR MAY QUALIFY AS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 (EUWA).

**GlaxoSmithKline Capital plc announces the repurchase and cancellation of certain outstanding GBP Notes**

13 February 2023.

GlaxoSmithKline Capital plc (the **Company**) announces today that it has purchased and cancelled the following GBP Notes issued under the Group's Euro Medium Term Note Programme:

Description of the Notes	ISIN / Common Code	Nominal amount of GBP purchased and cancelled	Aggregate Nominal Amount Outstanding after such purchase and cancellations
5.250 per cent. Notes due 19 December 2033	XS0140516864/ 014051686	£75,783,000	£574,166,000
6.375 per cent. Notes due 9 March 2039	XS0350820931/ 035082093	£68,700,000	£631,300,000

***The Company***

**GlaxoSmithKline Capital plc**

980 Great West Road  
Brentford  
Middlesex TW8 9GS  
United Kingdom

Email: [company.secretary@gsk.com](mailto:company.secretary@gsk.com)

**This announcement contains information that qualifies or may qualify as inside information. The person responsible for arranging the release of this announcement on behalf of GlaxoSmithKline Capital plc is Victoria Whyte, Company Secretary.**